CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03845296
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:47.096267+00:00
Published At: 2022-10-19T00:00:00+00:00
Record Updated At: 2025-05-21
Results Posted At: 2022-10-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Deleterious BRCA1 Gene Mutation", "Deleterious BRCA2 Gene Mutation", "Loss of Heterozygosity", "Lung Non-Small Cell Squamous Carcinoma", "Recurrent Large Cell Lung Carcinoma", "Recurrent Lung Adenocarcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Non-Squamous Non-Small Cell Lung Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-05-21"
protocolSection.identificationModule.nctId: "NCT03845296"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-10-19"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.